Other single compounds

(Unterschied zwischen Versionen)

Wechseln zu: Navigation, Suche

Version vom 18. Juni 2020, 12:57 Uhr

Ivermectin
32330482 ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors responses
32251768 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
32283237 ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?

on ivermectin

32322397 2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
32314704 2020. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency
32378737 2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19

Icatibant bradykinin antagonist
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?

Azithromycin
32302411 2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19

Teicoplanin
32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?

Doxycycline
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
32314492 ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak

Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen

Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19

Chlorpromazine retarget

paper

Lauric acid nat. compd.

call for trial

Nicotine nat. toxin

france

32353120 ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?
32242236 ä. COVID-19 and Smoking

Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Various Leads

32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?

PDE5 Inhibitors
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

Amantadine
32361028 ä. Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ?
32361100 2020. Amantadine as a drug to mitigate the effects of COVID-19

Glycyrrhizin
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19

Ipecac
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses

Camostat mesilate
32347443 ä. Camostat mesilate therapy for COVID-19

Nafamostat mesilate
32312781 2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

Sodium pyruvate
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients

alpha1 adrenergic antagonists
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists
32237190 ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy

Ciclesonide
32362440 ä. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases

Melatonin
32217117 2020. COVID-19: Melatonin as a potential adjuvant treatment
32360622 2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19
32334009 2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment
32347747 2020. Can melatonin reduce the severity of COVID-19 pandemic?

Oxytocin
32344303 ä. Oxytocin as a potential defence against Covid-19?

Resiniferatoxin
32292906 2020. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review

TRPV1 target
C7147214 ä. Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection

Botox
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19

PAK-1 target
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?

Endothelin antagonists
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?

Saikosaponins
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets

Dapsone
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19

Colchicine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32380315 ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis

Olanzapine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)

ADAM17 as target
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19

Dextrometorphan

dextrometorphan (antitussive compd)

Rho kinase inhibitors
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)

Nitazoxaide
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management

tPA

32312290 2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis

Plasminogen
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19

Metformin
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)

mTOR ihibitors
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
32334502 2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment

Cyclophilin A inhibitors
32347055 2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors

Alisporivir

32376613 2020. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025)

Cyclosporin A
32354685 ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

CD147
32307653 ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Bee venom
32360140 ä. Bee venom and SARS-CoV-2

Spironolactone
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?

Imatinib
32376403 ä. Imatinib might constitute a treatment option for lung involvement in COVID-19

Luteolin
32339387 2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin

BTK Bruton Tyrosine Kinase ibrutiib
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

alpha 1 antagonists cave fehlt 1 x

bradykinin antagonists cave felt was

32337769 2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2

32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

@@ Zeile 6: / Zeile 6: @@
 *[https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds on ivermectin]
 {{tp|p=32322397|t=2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance |pdf=|usr=}}
+{{tp|p=32314704|t=2020. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency |pdf=|usr=}}
+{{tp|p=32378737|t=2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of  COVID-19 |pdf=|usr=}}
 '''Icatibant''' bradykinin antagonist
@@ Zeile 13: / Zeile 15: @@
 '''Macrolide antibiotics'''
 {{tp|p=32249257|t=2020. Macrolide treatment for COVID-19: Will this be the way forward?|pdf=|usr=}}
+'''Azithromycin'''
+{{tp|p=32302411|t=2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and  Use in COVID-19 |pdf=|usr=}}
 '''Teicoplanin'''
@@ Zeile 19: / Zeile 24: @@
 '''Doxycycline'''
 {{tp|p=32339778|t=ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19 |pdf=|usr=}}
+{{tp|p=32314492|t=ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak |pdf=|usr=}}
@@ Zeile 79: / Zeile 84: @@
 '''Camostat mesilate'''
 {{tp|p=32347443|t=ä. Camostat mesilate therapy for COVID-19 |pdf=|usr=}}
+'''Nafamostat mesilate'''
+{{tp|p=32312781|t=2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |pdf=|usr=}}
 '''Sodium pyruvate'''
@@ Zeile 85: / Zeile 93: @@
 '''alpha1 adrenergic antagonists'''
 {{tp|p=32352407|t=2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor  antagonists |pdf=|usr=}}
+{{tp|p=32237190|t=ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy |pdf=|usr=}}
 '''Ciclesonide'''
@@ Zeile 93: / Zeile 103: @@
 {{tp|p=32360622|t=2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19 |pdf=|usr=}}
 {{tp|p=32334009|t=2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment |pdf=|usr=}}
+{{tp|p=32347747|t=2020. Can melatonin reduce the severity of COVID-19 pandemic?|pdf=|usr=}}
 '''Oxytocin'''
@@ Zeile 114: / Zeile 127: @@
 '''Saikosaponins'''
 {{tp|p=32353743|t=2020. Purposing Saikosaponins for the treatment of COVID-19 |pdf=|usr=}}
+{{tp|p=32345124|t=2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |pdf=|usr=}}
 '''Dapsone'''
@@ Zeile 123: / Zeile 139: @@
 '''Colchicine'''
 {{tp|p=32344275|t=2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) |pdf=|usr=}}
+{{tp|p=32380315|t=ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}}
 '''Olanzapine'''
@@ Zeile 131: / Zeile 150: @@
-'''Dextmetrorphan'''
+'''Dextrometorphan'''
 *[https://theconversation.com/we-found-and-tested-47-old-drugs-that-might-treat-the-coronavirus-results-show-promising-leads-and-a-whole-new-way-to-fight-covid-19-136789 dextrometorphan (antitussive compd)]
@@ Zeile 140: / Zeile 159: @@
 '''Nitazoxaide'''
 {{tp|p=32360581|t=ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for  COVID-19 early management |pdf=|usr=}}
+'''tPA'''
+{{ttp|p=32312290|t=2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis |pdf=|usr=}}
 '''Plasminogen'''
 {{tp|p=32275753|t=ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19 |pdf=|usr=}}
+'''Metformin'''
+{{tp|p=32313883|t=2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review) |pdf=|usr=}}
+'''mTOR ihibitors'''
+{{tp|p=32313883|t=2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review) |pdf=|usr=}}
+{{tp|p=32334502|t=2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral  Treatment|pdf=|usr=}}
 '''Cyclophilin A inhibitors'''
 {{tp|p=32347055|t=2020.  Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors  |pdf=|usr=}}
+'''Alisporivir'''
+{{ttp|p=32376613|t=2020. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) |pdf=|usr=}}
 '''Cyclosporin A'''
 {{tp|p=32354685|t=ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia |pdf=|usr=}}
+'''CD147'''
+{{tp|p=32307653|t=ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement |pdf=|usr=}}
+'''Bee venom'''
+{{tp|p=32360140|t=ä. Bee venom and SARS-CoV-2 |pdf=|usr=}}
+'''Spironolactone'''
+{{tp|p=32297520|t=2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?|pdf=|usr=}}
+'''Imatinib'''
+{{tp|p=32376403|t=ä. Imatinib might constitute a treatment option for lung involvement in COVID-19 |pdf=|usr=}}
+'''Luteolin'''
+{{tp|p=32339387|t=2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin |pdf=|usr=}}
+'''BTK Bruton Tyrosine Kinase''' ''ibrutiib''
+{{tp|p=32302379|t=2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients |pdf=|usr=}}
+'''alpha 1 antagonists''' cave fehlt 1 x
+'''bradykinin antagonists''' cave felt was
+{{ttp|p=32337769|t=2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |pdf=|usr=}}
+{{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}}

Other single compounds

Version vom 18. Juni 2020, 12:57 Uhr

Meine Werkzeuge

Namensräume

Varianten

Ansichten

Aktionen

Suche

Navigation

Werkzeuge